Results 121 to 130 of about 597,082 (181)

International Dermoscopy Society consensus recommendations for the management of lentigo maligna

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1600-1617, October 2026.
Lentigo maligna (LM) poses diagnostic and therapeutic challenges amid rising incidence and limited high‐quality evidence. This international expert consensus provides pragmatic, evidence‐based and expertise‐informed guidance on LM diagnosis and management.
Ana‐Maria Forsea   +52 more
wiley   +1 more source

Skin adnexal carcinoma with BRD3-NUTM2B fusion. [PDF]

open access: yesJ Cutan Pathol, 2021
Rubio Gonzalez B   +3 more
europepmc   +1 more source

Matrix Metalloproteinase 28-Bearing Microcystic Adnexal Carcinoma on the Back. [PDF]

open access: yesCase Rep Oncol, 2021
Chiba H   +4 more
europepmc   +1 more source

Microcystic Adnexal Carcinoma of the Lower lip: A Case Report

open access: yes, 2008
PURPOSE: Microcystic adnexal carcinoma is a rare malignant appendage tumor, first described by Goldstein et al in 1982. Here, we present our experience in treatment of a case on the lower lip.
나동균, 탁관철
core  

Treatment options for ocular adnexal lymphoma (OAL)

open access: yes, 2009
Victoria Mary Lendrum CohenSt. Bartholomew’s and Moorfields Eye Hospital, London UKAbstract: Most lymphomas that involve the ocular adnexal structure are low grade, B cell, non-Hodgkin’s lymphomas. The treatment depends upon the grade
Victoria Mary Lendrum Cohen
core  

Microcystic adnexal carcinoma. A case report [Il carcinoma microcistico annessiale. Descrizione di un caso.]

open access: yes, 1990
Microcystic adnexal carcinoma (MAC) is a rare cutaneous neoplasm, locally aggressive, recently recognized as a clinicopathologic entity. Histologically, MAC shows both ductal and pilar differentiation.
Politi M.   +4 more
core  

Cutaneous Microcystic Microsecretory Adenocarcinoma With Marked Adnexal Hyperplasia: A Simulant of Microcystic Adnexal Carcinoma

open access: yes
Microsecretory adenocarcinoma (MSA) was first described in 2019 as a low-grade salivary gland neoplasm of intraoral origin with distinct histopathologic features and a characteristic MEF2C::SS18 fusion.
Vellaichamy, Gautham   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy